Mode
Text Size
Log in / Sign up

Hematology

128 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Extracellular vesicles in RA: biomarkers and therapeutic vehicles, but clinical utility remains unproven
Hematology Sys. Review
Extracellular vesicles in RA: biomarkers and therapeutic vehicles, but clinical utility remains unproven Extracellular Vesicles May Offer New Paths for Rheumatoid Arthritis
This mini-review examines extracellular vesicles (EVs) in rheumatoid arthritis, highlighting their cargo of citrullinated proteins, miRNAs, …
Small particles called extracellular vesicles may help doctors track and treat rheumatoid arthritis by signaling immune responses and carryi…
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia
Hematology Phase III
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia PEG-asparaginase shows lower toxicity in childhood leukemia trial
This Phase 3 randomized controlled trial evaluated intravenous PEG-asparaginase (IV-PEG) versus intramuscular native E. coli L-asparaginase …
A new trial finds that PEG-asparaginase may cause fewer side effects than standard treatment for children with leukemia.
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation
Hematology Sys. Review
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation Extracellular Vesicles Show Potential for Managing Metabolic Health Conditions
This systematic review evaluates the role of extracellular vesicles (EVs) in managing obesity, type 2 diabetes, MASLD, and atherosclerosis. …
New research identifies specific molecules within extracellular vesicles that may play a role in managing obesity, diabetes, and liver disea…
FDA Approves Inrebic (fedratinib) for Intermediate-2 or High-Risk Myelofibrosis
Hematology FDA Approval
FDA Approves Inrebic (fedratinib) for Intermediate-2 or High-Risk Myelofibrosis FDA approves new pill Inrebic for rare bone marrow cancer.
The FDA approved Inrebic (fedratinib) for adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. The recommende…
The FDA approved Inrebic (fedratinib) for adults with a type of bone marrow cancer called myelofibrosis. It is a daily pill for patients wit…
FDA Approves Jakafi (ruxolitinib) for Steroid-Refractory Acute Graft-Versus-Host Disease
Hematology FDA Approval
FDA Approves Jakafi (ruxolitinib) for Steroid-Refractory Acute Graft-Versus-Host Disease FDA approves Jakafi for acute graft-versus-host disease in patients 12 and older.
The FDA approved Jakafi (ruxolitinib) for treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12…
The FDA approved Jakafi (ruxolitinib) to treat acute graft-versus-host disease (aGVHD) in people aged 12 and older who do not respond to ste…
FDA Approves Vonjo (pacritinib) for Myelofibrosis with Low Platelet Counts
Hematology FDA Approval
FDA Approves Vonjo (pacritinib) for Myelofibrosis with Low Platelet Counts FDA approves new drug Vonjo for rare bone marrow cancer with low platelets.
The FDA approved Vonjo (pacritinib) for adults with intermediate or high-risk primary or secondary myelofibrosis with platelet counts below …
The FDA approved Vonjo (pacritinib) for adults with myelofibrosis who have very low platelet counts. It helps reduce spleen size. This offer…
ctDNA and immune profiling offer a pathway toward individualized treatment for recurrent colorectal cancer
Hematology Sys. Review
ctDNA and immune profiling offer a pathway toward individualized treatment for recurrent colorectal cancer New tools help identify high risk of colorectal cancer relapse
This mini review explores ctDNA-guided surveillance, immune checkpoint blockade, and engineered cell therapies for patients with colorectal …
Doctors are using blood tests and immune profiling to better predict when colorectal cancer might return after treatment.
Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis
Hematology Meta-analysis
Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis Case report: Brain infection in autoimmune hepatitis patient
This case report describes the management of disseminated nocardiosis in a 55-year-old man with autoimmune hepatitis. The patient showed gra…
A man with autoimmune hepatitis developed a rare brain infection after immunosuppression. Doctors treated it successfully with targeted anti…
Piezoelectric osteotomy reduces edema, ecchymosis, and pain in patients undergoing rhinoplasty
Hematology Meta-analysis
Piezoelectric osteotomy reduces edema, ecchymosis, and pain in patients undergoing rhinoplasty Piezoelectric tools reduce swelling and bruising after nose surgery
This meta-analysis of 905 patients found that piezoelectric osteotomy significantly reduces postoperative edema, ecchymosis, and pain compar…
New research shows that using piezoelectric tools during nose surgery can significantly lower pain, bruising, and swelling for patients.
Acupuncture Modalities Show Distinct Benefits for Trigeminal Neuralgia
Hematology Meta-analysis
Acupuncture Modalities Show Distinct Benefits for Trigeminal Neuralgia New analysis shows acupuncture and bloodletting help trigeminal neuralgia
A network meta-analysis of 58 RCTs finds bloodletting therapy improves total effective rate and pain scores, while acupuncture combined with…
New research highlights how specific acupuncture techniques and bloodletting can reduce pain and attack frequency for those with trigeminal …
FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous for Multiple Myeloma
Hematology FDA Approval
FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous for Multiple Myeloma FDA approves new multiple myeloma drug Sarclisa Escena for injection under the skin.
The FDA approved Sarclisa Escena (isatuximab-irfc) subcutaneous injection for multiple myeloma in three combination regimens. It is indicate…
The FDA approved Sarclisa Escena (isatuximab-irfc) for subcutaneous injection to treat multiple myeloma. It can be used in three different d…
Immune microenvironment characterization provides a framework for precision immunotherapy in various thyroid cancer types
Hematology Sys. Review
Immune microenvironment characterization provides a framework for precision immunotherapy in various thyroid cancer types New Model Identifies Immune Pathways in Thyroid Cancer Treatment
This systematic review synthesizes the immune evolution of thyroid cancer from autoimmune-driven inflammation to exhausted states in advance…
A new framework maps how immune cells change in thyroid cancer, helping researchers identify better ways to target tumors and overcome treat…

All Hematology Articles